![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 10, 2012 09:49 ET
|
Merrimack Pharmaceuticals
Completion of $105 Million IPO
Five Therapeutic Candidates in the Clinic, Each Planned to be Developed With a Companion Diagnostic From Proprietary Network Biology Platform
Over 15 Clinical...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2012 Investor Conference Call
August 01, 2012 09:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2012 Investor Conference Call and webcast...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals, Inc. [MACK] to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 24, 2012
July 23, 2012 17:14 ET
|
Merrimack Pharmaceuticals
Biotech company has five novel therapeutic oncology candidates in clinical development
MM-398 in Phase 3 clinical study for patients with metastatic pancreatic cancer who have previously failed...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces the Addition of Former Deloitte Global CEO James H. Quigley to Its Board of Directors
July 16, 2012 16:33 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of James Quigley, CEO emeritus of Deloitte Touche Tohmatsu, Limited (the...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
William M. McClements Joins Merrimack Pharmaceuticals as Senior Vice President of Corporate Operations
July 09, 2012 17:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 9, 2012 (GLOBE NEWSWIRE) -- William M. McClements, a former executive at the Monitor Group, has joined Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) as Senior Vice President of...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals and Cancer Treatment Centers of America(R) Partner in Multifaceted Collaboration to Advance Translational Research and Individualized Treatment
June 28, 2012 16:52 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 28, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) and the Cancer Treatment Centers of America® (CTCA) announced today that they have formed a...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Announces Expansion of Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer
June 27, 2012 17:06 ET
|
Merrimack Pharmaceuticals
Expansion to Include MM-398 in Combination With 5-Fluorouracil and Leucovorin
Additional Arm Explores Broader Usage of MM-398 in a Setting Where Combination Therapy is Becoming More...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology Conference
June 26, 2012 16:59 ET
|
Merrimack Pharmaceuticals
Two Abstracts Selected for Oral Presentation
Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development
CAMBRIDGE, Mass., June...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Set to Join Russell 3000 Index
June 20, 2012 16:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 20, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces the Addition of Cancer Research Pioneer John Mendelsohn, M.D. to Its Board of Directors
June 18, 2012 16:09 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of John Mendelsohn, M.D., past president of The University of Texas MD...